Clin2
NCT07298928Possibly a fitNot yet recruiting

Telitacicept for children with ocular myasthenia gravis

Effectiveness

Treatments studied

Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.

This trial is testing a new drug called telitacicept for children with ocular myasthenia gravis (eye muscle weakness). It aims to see if the drug is safe and effective when added to standard treatments.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
30 people
Ages
Up to 18 years
Study type
Interventional

Who can take part

  • You must be under 18 years old.
  • You have been diagnosed with ocular myasthenia gravis (a condition that affects eye muscles).
  • You have been taking a stable dose of standard treatments like cholinesterase inhibitors or steroids.
  • You cannot have a current active infection, especially hepatitis B.
  • You cannot have severe liver or kidney disease, or certain immune deficiencies.
  • You cannot have had a thymectomy (thymus gland removal) within the last 3 months.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07249632Recruiting· Phase 3
Study of Telitacicept for Eye Muscle Weakness from Myasthenia Gravis

This trial tests a new drug, telitacicept, for people with myasthenia gravis that only affects the eyes (ocular myasthenia gravis). The goal is to see if it can improve symptoms like droopy eyelids or double vision.

Beijing, Beijing Municipality
NCT06456580Recruiting· Phase 3
Telitacicept for generalized myasthenia gravis

This trial tests a new medication called Telitacicept for people with generalized myasthenia gravis (gMG). The goal is to see if it can reduce muscle weakness and improve daily function. You may be able to join if you have moderate to severe symptoms and have not had recent thymoma or other serious health issues.

Scottsdale, Arizona
NCT07355257Not yet recruiting· Phase 2/Phase 3
Telitacicept for inflammatory muscle disease (myositis) trial

This trial tests an investigational drug called Telitacicept for people with inflammatory myopathies (muscle inflammation). It aims to see if the drug can help when standard treatments haven't worked well.

NCT06723548Not yet recruiting· Phase 4
Telitacicept and low-dose steroids for hard-to-treat myasthenia gravis

This trial tests a new medicine called telitacicept combined with low-dose steroids for people with hard-to-treat myasthenia gravis. The goal is to see if this combination can better control symptoms that haven't improved with standard treatments.

NCT06827587Not yet recruiting
Efgartigimod then Telitacicept for Myasthenia Gravis

This trial tests whether taking two drugs one after the other—efgartigimod followed by telitacicept—is safe and effective for people with generalized myasthenia gravis. It may offer a new treatment option if standard therapy isn't enough.

NCT06125405Recruiting· Phase 3
Telitacicept for children with frequently relapsing nephrotic syndrome

This trial tests a new drug called telitacicept to help children whose nephrotic syndrome keeps coming back often or who need steroids to stay in remission. The goal is to see if it can keep urine protein levels low and reduce relapses.

Hangzhou, Zhejiang

Hear when a new Effectiveness trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.